Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing